Clinical Trial Update: A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in Japanese adults and adolescents (6-64 years) and has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2019-12-10